Home > Drugs A – Z > Phentermine/Topiramate (By mouth)

Phentermine/Topiramate (By mouth)

Used with diet and exercise to help you reach and maintain a healthy weight.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Phentermine and topiramate combination is used together with a reduced-calorie diet and proper exercise to help you lose weight. It is also used in overweight people who may also have diabetes, high blood pressure, high cholesterol, or heart disease. This medicine is available only under a special restricted distribution program called Qsymia™ REMS program… Read more
Brand names include
Qsymia
Drug classes About this
Anticonvulsant, Appetite Suppressant, Centrally Acting

What works? Research summarized

Evidence reviews

Long‐term effects of weight‐reducing drugs in people with elevated blood pressure

Doctors often recommend that people who are overweight or obese with elevated blood pressure lose weight, which may include taking anti‐obesity drugs to assist in weight and blood pressure reduction. Two active ingredients (rimonabant and sibutramine) were withdrawn from the market in 2009 and 2010, respectively. Current guidelines for the pharmacological management of obesity quote five medications (orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide) that have been approved for long‐term weight reduction by the US Food and Drug Administration. However, two of these drugs (phentermine/topiramate and lorcaserin) did not obtain approval in Europe.

Effectiveness of Primary Care Interventions for Weight Management in Children and Adolescents: An Updated, Targeted Systematic Review for the USPSTF [Internet]

To examine behavioral and pharmacological weight management interventions for overweight (defined as BMI ≥ 85th to 94th percentile of age- and sex-specific norms) and/or obese (BMI ≥ 95th percentile) children and adolescents which are feasible to conduct in primary care settings or that may be available for referral from primary care in order to update an identified gap in the previous report on childhood obesity for the United States Preventive Services Task Force (USPSTF).

Eating Disorders: Core Interventions in the Treatment and Management of Anorexia Nervosa, Bulimia Nervosa and Related Eating Disorders

This guideline has been developed to advise on the identification, treatment and management of the eating disorders anorexia nervosa, bulimia nervosa and related conditions. The guideline recommendations have been developed by a multidisciplinary group of health care professionals, patients and their representatives, and guideline methodologists after careful consideration of the best available evidence. It is intended that the guideline will be useful to clinicians and service commissioners in providing and planning high quality care for those with eating disorders while also emphasising the importance of the experience of care for patients and carers.

See all (7)

Summaries for consumers

Long‐term effects of weight‐reducing drugs in people with elevated blood pressure

Doctors often recommend that people who are overweight or obese with elevated blood pressure lose weight, which may include taking anti‐obesity drugs to assist in weight and blood pressure reduction. Two active ingredients (rimonabant and sibutramine) were withdrawn from the market in 2009 and 2010, respectively. Current guidelines for the pharmacological management of obesity quote five medications (orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide) that have been approved for long‐term weight reduction by the US Food and Drug Administration. However, two of these drugs (phentermine/topiramate and lorcaserin) did not obtain approval in Europe.

Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus

Obesity is closely related to type 2 diabetes and weight reduction is an important part of the care delivered to obese persons with diabetes. This review of drugs for weight loss among adults with type 2 diabetes revealed weight loss of between 2.0 and 5.1 kg for fluoxetine, orlistat and sibutramine at follow‐up of up to 57 weeks. The long‐term effects remain uncertain. Adverse events were common in all three drugs: gastrointestinal side effects with orlistat; tremor, somnolence, and sweating with fluoxetine; and palpitations with sibutramine. There were few studies examining other drugs used for weight loss in populations with diabetes.

PubMed Health Blog...

read all...